The US Food and Drug Administration (FDA) has accepted for filing and priority review of the new drug application (NDA) for Sentynl Therapeutics' CUTX-101 (copper histidinate) for the treatment of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback